Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03804944
Title Converting HR+ Breast Cancer Into an Individualized Vaccine (CBCV)
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Weill Medical College of Cornell University
Indications

Her2-receptor negative breast cancer

Therapies

CDX-301

CDX-301 + Pembrolizumab

Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.